Identifying and Developing Breakthrough Medicines

Bexion Pharmaceuticals is a mid-stage clinical company developing life-changing treatments in Oncology and CNS.

The company’s lead compound, BXQ-350, is a potent, first in class anti-tumor S1P agent has the potential to normalize sphingolipid metabolism in cancer cells and reverse oxaliplatin resistance. Oxaliplatin is the Standard of Care for the treatment of mCRC but up to 90% of patients may suffer from Chemotherapy Induced Peripheral Neuropathy (CIPN) a painful, debilitating condition that occurs when nerve cells of the peripheral nervous system are damaged or destroyed by chemotherapeutic agents.

With our highly experienced biotech leadership team and expertise in Oncology, we are urgently progressing our pipeline to develop life-changing oncology therapies on our path to becoming a leading biotech/pharmaceutical company.

Bexion’s Leadership

Scott Shively

Scott Shively

President & CEO

Ray Takigiku, Ph.D.

Ray Takigiku, Ph.D.

Founder and Chief Scientific Officer

Joyce LaViscount

Joyce LaViscount

Chief Financial Officer

Jim Beach

Jim Beach

Chief Operations Officer

Michael Gazda, Ph.D.

Michael Gazda, Ph.D.

Vice President of Chemistry, Manufacturing, and Controls

Margaret van Gilse, M.B.A.

Vice President of Business Development

Gilles Tapolsky, PhD, M.B.A.

Gilles Tapolsky, PhD, M.B.A.

Vice President of Pharmacology

Christy Rothwell, Ph.D., J.D.

Christy Rothwell, Ph.D., J.D.

IP, Legal Counsel

Richard C. Curry III, M.D.

Richard C. Curry III, M.D.

Medical Affairs Advisor

Shabnam Kazmi, M.B.A.

Shabnam Kazmi, M.B.A.

Commercialization Advisor

Richard J. Schwen, Ph.D., D.A.B.T, R.A.C.

Richard J. Schwen, Ph.D., D.A.B.T, R.A.C.

Regulatory Advisor

Board of Directors

Charles R. Scheper – Chairman of the Board

Mr. Chuck Scheper was the Chief Operating Officer at Great American Financial Resources, a $20 billion life and annuity company until his retirement in 2010. Prior to that position, Mr. Scheper was president and chief executive officer of Manhattan National Life Insurance Company and president of Pioneer Financial Services. Chuck is a cancer survivor and his journey to wellness led him to become active in various causes related to cancer, including Cancer Support Community, where he has served as the National Board Chairperson and board member. Currently, he is also the Chair of Catalytic Development Funding Corp of Northern Kentucky and Covington Economic Development Authority.

Scott Shively – President & CEO

Scott Shively is an experienced Founder, CEO and CCO in the US and international biopharma markets. He previously served as CEO and Co-founder of Neumentum, Inc. During his career, Mr. Shively has achieved outstanding financial results and growth in value for shareholders and has been involved in several successful exits for small-to-mid-sized biopharma companies. He spent a number of years at Pfizer where he led global commercial efforts for the Pain and CNS areas, including responsibility for products such as LYRICA® (pregabalin) and CELEBREX® (celecoxib) as well as the development pipeline.

Cameron Durrant, MD, MBA – Board Member

Dr. Cameron Durrant is the Chairman and Chief Executive Officer of Humanigen. He has held executive positions at major global pharmaceutical companies, including Merck & Co., GlaxoSmithKline and Pharmacia. Dr. Durrant has served as board chairman, lead independent director and as CEO for several specialty pharma or biotech companies in both the private and public sector. He has been involved in several exits and has raised significant funding from a variety of sources.

Timothy Schroeder – Board Member

Timothy Schroeder, CEO and Founder of CTI Clinical Trial and Consulting Services, has over 35 years of clinical, academic, and industry experience in global drug and device development programs. CTI, founded in 1999, is a multi-national clinical research firm with associates in North America, Europe, Latin America and Asia-Pacific. The firm, which is one of the 20 largest CROs in the world, has supported more than 100 drug and device approvals and currently works on behalf of approximately 135 global pharmaceutical and biotechnology companies.

Raymond J. Tesi, M.D.-Board Member

Dr. Tesi has a distinguished career as a biotech entrepreneur and an experienced surgeon. Currently, he is President, Chief Executive Officer and acting Chief Medical Officer of INmune Bio (NASDAQ: INMB). Prior to his role at INMB, he held leadership positions in several biotech companies in both the development and commercial sides of the businesses with responsibility for all phases of drug development, product positioning and launch, post-approval marketing support, while supporting investor relations and business development. Dr. Tesi has been an academic transplant surgeon since 1982, receiving his MD degree from Washington University School of Medicine, and has been a Fellow of the American College of Surgery since 1991.

Olivia F. Kirtley, CPA, CGMA – Board Member

Ms. Olivia Kirtley, a Certified Public Accountant and Chartered Global Management Accountant, is a highly experienced business consultant on strategic, risk and corporate governance issues. Her career spans tenures as a corporate executive and public accounting, including as Chief Financial Officer of an international company and senior tax manager at a predecessor firm to Ernst & Young. Ms. Kirtley is also a recognized leader of the accountancy profession in the U. S. and globally, having served as President and Chairman of the International Federation of Accountants (IFAC) and Chairman of the American Institute of Certified Public Accountants (AICPA). She has extensive public and private company board experience and is currently a director of U.S. Bancorp and Papa John’s International.

Keith A. Carlson – Board Member

Keith Carlson is Co-founder, CEO and Managing Partner of Roebling Capital Partners, a lower-middle-market private equity fund that completes controlling equity transactions. He leverages two decades of experience in buy and sell-side M&A transactions, corporate finance, strategy and capital markets. Mr. Carlson is also an acting Managing Director of M&A and Shareholder at VonLehman, a CPA and Advisory Firm.

Scientific Advisors

Xiaoyang Qi, Ph.D.

Professor of Medicine
Co-Division Chief for Basic Science Research
Division of Hematology-Oncology
Department of Internal Medicine
University of Cincinnati College of Medicine

Andrew M. Lowy, M.D.

Professor of Surgery
Chief, Division of Surgical Oncology
UC San Diego Health
Department of Surgery

Nita J. Maihle, Ph.D.

Associate Cancer Center Director, University of Mississippi Medical Center

Joanna Groden, Ph.D.

Vice Chancellor for Research
University of Illinois at Chicago

Olivier Rixe, M.D., Ph.D.

VP, Early Clinical Development at Daiichi Sankyo, Inc.
Quantum Santa Fe

Bexion Completed and Planned Milestones

Bexion milestones

Commitment to Patient Advocacy

Bexion Pharmaceuticals is proud to collaborate with patient organizations to better support the oncology community. We actively engage with our advocacy partners to learn more about their needs which guides our ongoing activities and ensures that our priorities are best aligned with the priorities of patients and their families.

To learn more about advocacy partnership opportunities, please click on the contact information tab below.

Our Advocacy Partners

CancerFree Kids logo
Cancer Support Community logo